RT Journal Article
T1 Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
A1 Iborra, Marisa
A1 Gisbert, Javier P
A1 Bosca-Watts, Marta Maia
A1 Lopez-Garcia, Alicia
A1 Garcia-Sanchez, Valle
A1 Lopez-Sanroman, Antonio
A1 Hinojosa, Esther
A1 Marquez, Lucia
A1 Garcia-Lopez, Santiago
A1 Chaparro, Maria
A1 Aceituno, Montserrat
A1 Calafat, Margalida
A1 Guardiola, Jordi
A1 Belloc, Blanca
A1 Ber, Yolanda
A1 Bujanda, Luis
A1 Beltran, Belen
A1 Rodriguez-Gutierrez, Cristina
A1 Barrio, Jesus
A1 Cabriada, Jose Luis
A1 Rivero, Montserrat
A1 Camargo, Raquel
A1 van Domselaar, Manuel
A1 Villoria, Albert
A1 Schuterman, Hugo Salata
A1 Hervas, David
A1 Nos, Pilar
K1 Adalimumab
K1 Ulcerative colitis
K1 Treatment
AB Background Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors ofremission to ADA. Methods This cohort study used data from the ENEIDAregistry. Clinical response, clinical remission, endoscopicremission, adverse events (AE), colectomy, and hospitalisations were evaluated; baseline characteristics and biological parameters were compared to determine predictors of response. Results We included 263 patients (87 naı¨ve and 176 previously exposed to anti-tumour necrosis factor alpha, TNF). After 12 weeks, clinical response, clinical remission, and endoscopic remission rates were 51, 26, and 14 %, respectively. The naı¨ve group demonstrated betterresponse to treatment than the anti-TNF-exposed group at short-term. Clinical and endoscopic remission within 1 year of treatment was better in the naı¨ve group (65 vs. 49 and 50 vs. 35 %, respectively). The rates of AE, doseescalation, hospitalisations, and colectomy during the first year were higher in anti-TNF-exposed patients (40, 43, and 27 % vs. 26, 21, and 11 %, respectively). Patients withprimary failure and intolerance to the first anti-TNF and severe disease were associated with worse clinical response. Primary non-response to prior anti-TNF treatment and severe disease were predictive of poorer clinical remission. Low levels of C-reactive protein (CRP) and faecal calprotectin (FC) at baseline were predictors of clinical remission.Conclusions In clinical practice, ADA was effective in UC, especially in anti-TNF naı¨ve patients. FC and CRP could be predictors of treatment effectiveness.
PB Springer
YR 2016
FD 2016-09-28
LK http://hdl.handle.net/10668/10635
UL http://hdl.handle.net/10668/10635
LA en
NO Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, et al. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol. 2017 Jul;52(7):788-799
DS RISalud
RD Apr 5, 2025